Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of Therapy.
Suzanne GeorgeRobin L JonesSebastian BauerYoon-Koo KangPatrick SchöffskiFerry EskensOlivier MirPhillipe A CassierCesar SerranoWilliam D TapJonathan TrentPiotr RutkowskiShreyaskumar PatelSant P ChawlaEval MeiriMichael GordonTeresa ZhouMaria RocheMicahel C HeinrichMargaret von MehrenPublished in: The oncologist (2021)
In the NAVIGATOR trial, avapritinib, an inhibitor of KIT and platelet-derived growth factor receptor A tyrosine kinases, provided durable responses in a proportion of patients with advanced gastrointestinal stromal tumors (GIST) who had received three or more prior therapies. Avapritinib had a tolerable safety profile, with cognitive adverse events manageable with dose interruptions and modification in most cases. These findings indicate that avapritinib can elicit durable treatment responses in some patients with heavily pretreated GIST, for whom limited treatment options exist.